Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alnylam Pharmaceuticals Inc ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.


NDAQ:ALNY - Post by User

Post by edwardebreen15on Aug 22, 2022 8:59am
125 Views
Post# 34910822

RNA Interference (RNAi) Drug Delivery Market Size 2022-27

RNA Interference (RNAi) Drug Delivery Market Size 2022-27

According to IMARC Group’s latest report, titled “RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the global market reached a value of US$ 54.74 Billion in 2021. RNA interference (RNAi) drug delivery is a fundamental cellular mechanism that studies gene functions in eukaryotic organisms. It is also essential for silencing gene expressions for the development of new drugs. RNAi is considered a potential approach for treating various pathologic conditions, including cardiovascular diseases (CVDs), viral infections and cancer. It includes nonviral delivery of siRNA and viral delivery of shRNA that is used across various preclinical models and molecular targets for its transformational effect on modern medicine.

 

Request for a PDF sample of this report: https://www.imarcgroup.com/rna-interference-drug-delivery-market

 

The global RNA interference (RNAi) drug delivery market is primarily driven by the increasing number of academic research institutes performing RNA therapeutic studies. The rising prevalence of chronic diseases, such as cardiac defects and cancer, is also propelling the growth of the market. In recent years, the demand for RNAi has escalated due to its high level of specificity, minor side effects, and ease of synthesis. Besides this, siRNA or microRNAs (miRNA) helps in developing personalized medicines and identifying altered cellular molecules and metabolites. Furthermore, advancements in the field of nanotechnology that facilitate nanoparticle drug delivery and the overall improvements in the healthcare infrastructure are expected to provide a positive impact on the market. Looking forward, IMARC Group expects the global RNA interference (RNAi) drug delivery market to reach US$ 184.98 Billion by 2027, exhibiting at a CAGR of 22.5% during 2022-2027.

 

Checkout Now: https://www.imarcgroup.com/checkout?id=2758&method=1

 

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

 

Competitive Landscape with Key Players:

  • Alnylam Pharmaceuticals Inc.
  • Arrowhead Pharmaceuticals Inc.
  • CureVac AG
  • Dicerna Pharmaceuticals Inc.
  • Gradalis Inc.
  • Ionis Pharmaceuticals Inc
  • Merck & Co. Inc.
  • Moderna Inc.
  • Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
  • Silence Therapeutics Plc
  • Sirnaomics Inc.

Market Segmentation:

 

Breakup by Application:

  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others

Breakup by Technology:

  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)

Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/rna-interference-drug-delivery-market

 

Key highlights of the report:                                                    

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • Impact of COVID-19
  • Value Chain Analysis
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

 

Related Reports by IMARC Group:

Multiple Sclerosis Therapies Market: https://www.imarcgroup.com/multiple-sclerosis-therapies-market

Portable Medical Ventilators Market: https://www.imarcgroup.com/portable-medical-ventilators-market

Nucleic Acid Labelling Market: https://www.imarcgroup.com/nucleic-acid-labelling-market

Latin America Generic Drug Market: https://www.imarcgroup.com/latin-america-generic-drug-market

North Africa Generic Drug Market: https://www.imarcgroup.com/north-africa-generic-drug-market

 

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

 

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

 

Contact Us:

IMARC Group

30 N Gould St Ste R

Sheridan, WY 82801 USA - Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas: - +1 631 791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Bullboard Posts
Next >>